R A Balk - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

R A Balk

Showing results (41-50 of 46) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 46 results.

Chest|June 1, 1992

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care MedicineR C Bone, R A Balk, F B Cerra, et al.

The New England Journal of Medicine|June 27, 1996

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study GroupC J Fisher, J M Agosti, S M Opal, et al.

JAMA|February 7, 2001

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study InvestigatorsD C Angus, M C Birmingham, R A Balk, et al.

Critical Care Medicine|June 1, 1995

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study GroupR C Bone, R A Balk, A M Fein, et al.

JAMA|June 15, 1994

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study GroupC J Fisher, J F Dhainaut, S M Opal, et al.

Critical Care Medicine|July 1, 1997

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator GroupS M Opal, C J Fisher, J F Dhainaut, et al.

Pageof 5

Search research articles

Showing results (41-50 of 46) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 46 results.

Chest|June 1, 1992

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care MedicineR C Bone, R A Balk, F B Cerra, et al.

The New England Journal of Medicine|June 27, 1996

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study GroupC J Fisher, J M Agosti, S M Opal, et al.

JAMA|February 7, 2001

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study InvestigatorsD C Angus, M C Birmingham, R A Balk, et al.

Critical Care Medicine|June 1, 1995

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study GroupR C Bone, R A Balk, A M Fein, et al.

JAMA|June 15, 1994

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study GroupC J Fisher, J F Dhainaut, S M Opal, et al.

Critical Care Medicine|July 1, 1997

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator GroupS M Opal, C J Fisher, J F Dhainaut, et al.

Pageof 5